PROCEPT BioRobotics (NASDAQ: PRCT) Q1 2026 revenue rises 20%

Rhea-AI Filing Summary

PROCEPT BioRobotics reported first-quarter 2026 revenue of $83.1 million, up 20% from $69.2 million a year earlier, driven by higher system sales, consumables, and service, mainly in the United States.

Gross margin improved slightly to 65%, but the company’s net loss widened to $31.6 million, reflecting increased research, sales, and administrative spending to support growth. Operating cash outflow was $38.1 million, and cash and cash equivalents totaled $245.6 million with $52.0 million of term debt outstanding. The global installed base reached 971 robotic systems, including 765 in the U.S.

Key Figures

Revenue: $83.1 million Net loss: $31.6 million Gross margin: 65% +5 more

8 metrics

Revenue $83.1 million Three months ended March 31, 2026

Net loss $31.6 million Three months ended March 31, 2026

Gross margin 65% Three months ended March 31, 2026

Cash and cash equivalents $245.6 million Balance as of March 31, 2026

Net cash used in operating activities $38.1 million Three months ended March 31, 2026

Long-term debt $51.7 million Term loan facility balance as of March 31, 2026

Installed robotic systems 971 systems Global installed base as of March 31, 2026

U.S. revenue share 87% Portion of total revenue in Q1 2026

Key Terms

Aquablation therapy, benign prostatic hyperplasia, sales-type leases, stock-based compensation, +1 more

5 terms

Aquablation therapy medical

"Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging..."

A minimally invasive procedure that uses a doctor-guided, high‑velocity waterjet controlled by imaging and robotic guidance to remove excess prostate tissue causing urinary obstruction. Think of it like a precision pressure washer that cuts away problem tissue while preserving surrounding structures. Investors watch aquablation because its clinical outcomes, procedure time, complication rates, and reimbursement prospects influence demand for the devices and services that enable the treatment.

benign prostatic hyperplasia medical

"AquaBeam Robotic System...for the treatment of benign prostatic hyperplasia, a prostate gland enlargement condition."

Benign prostatic hyperplasia is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms like weak stream, urgency, and incomplete emptying; think of it as a garden hose being pinched so water flow slows. It matters to investors because it creates steady demand for medications, medical devices and procedures, regulatory approvals, and insurance coverage decisions—factors that can drive revenue and growth in healthcare companies serving an aging population.

sales-type leases financial

"Net investment in sales-type leases | $ | 4,779 | $ | 4,801"

stock-based compensation financial

"Total stock-based compensation recognized, before taxes, are as follows (in thousands)"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

Term Loan Facility financial

"The Agreement provides for a senior secured term loan facility in the aggregate principal amount of $52.0 million (the "Term Loan Facility")"

A term loan facility is a type of loan provided by a lender that is repaid over a set period of time, usually with fixed payments. It functions like a large, upfront loan that a borrower agrees to pay back gradually, often used to fund major investments or projects. For investors, understanding a company's use of such loans helps assess its financial stability and risk level.

10-Q Quarterly Reports: What Changes Quarter to Quarter →

000158897812/312026FALSEQ1one456xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureprct:buildingutr:sqftprct:renewalOptionprct:segment00015889782026-01-012026-03-3100015889782026-04-2400015889782026-03-3100015889782025-12-3100015889782025-01-012025-03-310001588978us-gaap:CommonStockMember2025-12-310001588978us-gaap:AdditionalPaidInCapitalMember2025-12-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001588978us-gaap:RetainedEarningsMember2025-12-310001588978us-gaap:CommonStockMember2026-01-012026-03-310001588978us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001588978us-gaap:RetainedEarningsMember2026-01-012026-03-310001588978us-gaap:CommonStockMember2026-03-310001588978us-gaap:AdditionalPaidInCapitalMember2026-03-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001588978us-gaap:RetainedEarningsMember2026-03-310001588978us-gaap:CommonStockMember2024-12-310001588978us-gaap:AdditionalPaidInCapitalMember2024-12-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001588978us-gaap:RetainedEarningsMember2024-12-3100015889782024-12-310001588978us-gaap:CommonStockMember2025-01-012025-03-310001588978us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001588978us-gaap:RetainedEarningsMember2025-01-012025-03-310001588978us-gaap:CommonStockMember2025-03-310001588978us-gaap:AdditionalPaidInCapitalMember2025-03-310001588978us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001588978us-gaap:RetainedEarningsMember2025-03-3100015889782025-03-310001588978us-gaap:FairValueInputsLevel1Member2026-03-310001588978us-gaap:FairValueInputsLevel2Member2026-03-310001588978us-gaap:FairValueInputsLevel3Member2026-03-310001588978us-gaap:FairValueInputsLevel1Member2025-12-310001588978us-gaap:FairValueInputsLevel2Member2025-12-310001588978us-gaap:FairValueInputsLevel3Member2025-12-3100015889782025-01-012025-12-310001588978prct:ManufacturingAndComputerEquipmentAndFurnitureAndFixturesMember2026-03-310001588978prct:ManufacturingAndComputerEquipmentAndFurnitureAndFixturesMember2025-12-310001588978prct:LaboratoryEquipmentMember2026-03-310001588978prct:LaboratoryEquipmentMember2025-12-310001588978us-gaap:EquipmentMember2026-03-310001588978us-gaap:EquipmentMember2025-12-310001588978us-gaap:LeaseholdImprovementsMember2026-03-310001588978us-gaap:LeaseholdImprovementsMember2025-12-310001588978us-gaap:ConstructionInProgressMember2026-03-310001588978us-gaap:ConstructionInProgressMember2025-12-310001588978us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2026-03-310001588978us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2025-12-310001588978us-gaap:OtherNoncurrentAssetsMember2026-03-310001588978us-gaap:OtherNoncurrentAssetsMember2025-12-310001588978exch:CIBCus-gaap:SeniorLoansMember2022-10-310001588978prct:SecuredOvernightFinancingRateOneMonthTermMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-012022-10-310001588978prct:SecuredOvernightFinancingRateThreeMonthTermMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-012022-10-310001588978prct:SecuredOvernightFinancingRateSixMonthTermMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-012022-10-310001588978prct:SecuredOvernightFinancingRateFloorRateMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-012022-10-310001588978prct:SecuredOvernightFinancingRateMarginRateMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-012022-10-310001588978exch:CIBCus-gaap:SeniorLoansMember2026-03-310001588978exch:CIBCus-gaap:SeniorLoansMember2025-03-310001588978us-gaap:NonUsMemberexch:CIBCus-gaap:SeniorLoansMember2022-10-310001588978exch:CIBCsrt:MaximumMemberus-gaap:SeniorLoansMember2026-03-310001588978exch:CIBCsrt:MinimumMemberus-gaap:SeniorLoansMember2026-03-310001588978us-gaap:BuildingMember2021-12-3100015889782021-12-312021-12-3100015889782021-12-310001588978prct:GrossReceivablesMember2026-03-310001588978prct:GrossReceivablesMember2025-12-310001588978prct:UnearnedInterestIncomeMember2026-03-310001588978prct:UnearnedInterestIncomeMember2025-12-310001588978us-gaap:AccountsReceivableMember2026-03-310001588978us-gaap:AccountsReceivableMember2025-12-310001588978us-gaap:OtherCurrentAssetsMember2026-03-310001588978us-gaap:OtherCurrentAssetsMember2025-12-310001588978us-gaap:CostOfSalesMember2026-01-012026-03-310001588978us-gaap:CostOfSalesMember2025-01-012025-03-310001588978us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001588978us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001588978us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001588978us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001588978prct:A2021EquityIncentiveAwardPlanMember2026-03-310001588978us-gaap:EmployeeStockOptionMember2025-12-310001588978us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001588978us-gaap:EmployeeStockOptionMember2026-03-310001588978us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001588978us-gaap:RestrictedStockUnitsRSUMember2025-12-310001588978us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001588978us-gaap:RestrictedStockUnitsRSUMember2026-03-310001588978prct:A2021EquityIncentiveAwardPlanMemberus-gaap:PerformanceSharesMember2026-01-012026-03-310001588978us-gaap:PerformanceSharesMember2025-12-310001588978us-gaap:PerformanceSharesMember2026-01-012026-03-310001588978us-gaap:PerformanceSharesMember2026-03-310001588978prct:EmployeeStockPurchasePlanMember2026-01-012026-03-310001588978prct:EmployeeStockPurchasePlanMember2026-03-310001588978us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001588978us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001588978prct:RestrictedStockUnitsRSUsAndPreferredStockUnitsPSUsMember2026-01-012026-03-310001588978prct:RestrictedStockUnitsRSUsAndPreferredStockUnitsPSUsMember2025-01-012025-03-310001588978prct:EmployeeStockPurchasePlanMember2026-01-012026-03-310001588978prct:EmployeeStockPurchasePlanMember2025-01-012025-03-310001588978prct:SystemSalesAndRentalsMembercountry:US2026-01-012026-03-310001588978prct:SystemSalesAndRentalsMembercountry:US2025-01-012025-03-310001588978prct:HandPiecesAndOtherConsumablesMembercountry:US2026-01-012026-03-310001588978prct:HandPiecesAndOtherConsumablesMembercountry:US2025-01-012025-03-310001588978prct:ServiceRevenueMembercountry:US2026-01-012026-03-310001588978prct:ServiceRevenueMembercountry:US2025-01-012025-03-310001588978country:US2026-01-012026-03-310001588978country:US2025-01-012025-03-310001588978prct:SystemSalesAndRentalsMemberus-gaap:NonUsMember2026-01-012026-03-310001588978prct:SystemSalesAndRentalsMemberus-gaap:NonUsMember2025-01-012025-03-310001588978prct:HandPiecesAndOtherConsumablesMemberus-gaap:NonUsMember2026-01-012026-03-310001588978prct:HandPiecesAndOtherConsumablesMemberus-gaap:NonUsMember2025-01-012025-03-310001588978prct:ServiceRevenueMemberus-gaap:NonUsMember2026-01-012026-03-310001588978prct:ServiceRevenueMemberus-gaap:NonUsMember2025-01-012025-03-310001588978us-gaap:NonUsMember2026-01-012026-03-310001588978us-gaap:NonUsMember2025-01-012025-03-310001588978country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-03-310001588978country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001588978us-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-03-310001588978us-gaap:NonUsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001588978prct:KevinWatersMemberprct:WatersRule10b51PlanMember2026-01-012026-03-310001588978prct:KevinWatersMemberprct:WatersRule10b51PlanMember2026-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from   to

Commission file number 001-40797

PROCEPT BioRobotics Corporation

(Exact name of registrant as specified in its charter)

Delaware									26-0199180
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)
150 Baytech Drive			San Jose			CA			95134
(Address of Principal Executive Offices)									(Zip Code)

(650) 232-7200

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.00001 par value per share			PRCT			Nasdaq Global Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  ☒   No  ☐ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer			☒			Accelerated filer			☐
Non-accelerated filer			☐			Smaller reporting company			☐
						Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes   ☐     No  ☒

The registrant had outstanding 56,918,844 shares of common stock as of April 24, 2026.

PROCEPT BioRobotics Corporation

Form 10-Q – QUARTERLY REPORT

For the Quarter Ended March 31, 2026

TABLE OF CONTENTS

						Page
Part I. Financial Information
Item 1.			Condensed Consolidated Financial Statements (unaudited)			4
			Condensed Consolidated Balance Sheets			4
			Condensed Consolidated Statements of Operations and Comprehensive Loss			5
			Condensed Consolidated Statements of Stockholders’ Equity			6
			Condensed Consolidated Statements of Cash Flows			7
			Notes to Condensed Consolidated Financial Statements			8
Item 2.			Management’s Discussion and Analysis of Financial Condition and Results of Operations			18
Item 3.			Quantitative and Qualitative Disclosure About Market Risk			26
Item 4.			Controls and Procedures			26
Part II. Other Information
Item 1.			Legal Proceedings			27
Item 1A.			Risk Factors			27
Item 2.			Unregistered Sales of Equity Securities and Use of Proceeds			27
Item 3.			Defaults Upon Senior Securities			27
Item 4.			Mine Safety Disclosures			27
Item 5.			Other Information			27
Item 6.			Exhibits			28
			Signatures

__________________

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “can”, “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this Quarterly Report, including without limitation statements regarding our business model and strategic plans for our products, technologies and business, including our implementation thereof, the timing of and our ability to obtain and maintain regulatory approvals, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the commercial success and market acceptance of our products, the sufficiency of our cash, cash equivalents and short-term investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.

The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Quarterly Report entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon these forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

3

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

(unaudited)

			March 31,						December 31,
			2026						2025
Assets
Current assets:
Cash and cash equivalents			$	245,641					$	286,503
Accounts receivable, net			96,388						83,533
Inventory			77,536						70,694
Prepaid expenses and other current assets			8,469						9,648
Total current assets			428,034						450,378
Restricted cash, non-current			3,038						3,038
Property and equipment, net			31,739						30,399
Operating lease right-of-use assets, net			17,162						17,538
Intangible assets, net			640						709
Other assets			6,449						6,019
Total assets			$	487,062					$	508,081
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable			$	18,851					$	17,285
Accrued compensation			18,476						23,175
Deferred revenue			13,702						13,048
Operating lease, current			2,358						2,214
Other current liabilities			10,249						10,073
Total current liabilities			63,636						65,795
Long-term debt			51,664						51,615
Operating lease, non-current			23,974						24,654
Other non-current liabilities			121						147
Total liabilities			139,395						142,211
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.00001 par value;
Authorized shares: 10,000 at March 31, 2026 and December 31, 2025
Issued and outstanding shares: none at March 31, 2026 and December 31, 2025			—						—
Common stock, $0.00001 par value;
Authorized shares: 300,000 at March 31, 2026 and December 31, 2025
Issued and outstanding shares: 56,897 and 56,323 at March 31, 2026 and December 31, 2025, respectively			—						—
Additional paid-in capital			1,020,881						1,007,390
Accumulated other comprehensive gain (loss)			(19)						37
Accumulated deficit			(673,195)						(641,557)
Total stockholders’ equity			347,667						365,870
Total liabilities and stockholders’ equity			$	487,062					$	508,081

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share data)

(unaudited)

			Three Months Ended March 31,
			2026						2025
Revenue			$	83,132					$	69,162
Cost of sales			29,185						25,001
Gross profit			53,947						44,161
Operating expenses:
Research and development			21,465						16,402
Selling, general and administrative			65,088						55,197
Total operating expenses			86,553						71,599
Loss from operations			(32,606)						(27,438)
Interest expense			(818)						(877)
Interest and other income, net			1,743						3,531
Loss before provision for income taxes			(31,681)						(24,784)
Provision for income taxes			(43)						(47)
Net loss			$	(31,638)					$	(24,737)
Net loss per share, basic and diluted			$	(0.56)					$	(0.45)
Weighted-average common shares used to
compute net loss per share attributable to
common shareholders, basic and diluted			56,511						54,917
Other comprehensive loss:
Foreign currency translation adjustment			(56)						109
Comprehensive loss			$	(31,694)					$	(24,628)

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

(unaudited)

			Common Stock												Additional Paid-in Capital						Accumulated Other Comprehensive Gain (Loss)						Accumulated Deficit						Total Stockholders' Equity
			Shares						Amount
Balance at December 31, 2025			56,323						$	—					$	1,007,390					$	37					$	(641,557)					$	365,870
Issuance of common stock under stock plans			574						—						222						—						—						222
Stock-based compensation expense			—						—						13,269						—						—						13,269
Foreign currency translation adjustment			—						—						—						(56)						—						(56)
Net loss			—						—						—						—						(31,638)						(31,638)
Balance at March 31, 2026			56,897						$	—					$	1,020,881					$	(19)					$	(673,195)					$	347,667

			Common Stock												Additional Paid-in Capital						Accumulated Other Comprehensive Gain (Loss)						Accumulated Deficit						Total Stockholders' Equity
			Shares						Amount
Balance at December 31, 2024			54,718						$	—					$	948,091					$	114					$	(545,985)					$	402,220
Issuance of common stock under stock plans			560						—						1,298						—						—						1,298
Stock-based compensation expense			—						—						10,267						—						—						10,267
Foreign currency translation adjustment			—						—						—						109						—						109
Net loss			—						—						—						—						(24,737)						(24,737)
Balance at March 31, 2025			55,278						$	—					$	959,656					$	223					$	(570,722)					$	389,157

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

PROCEPT BioRobotics Corporation

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

			Three Months Ended March 31,
			2026						2025
Cash flows from operating activities:
Net loss			$	(31,638)					$	(24,737)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization			1,735						1,475
Stock-based compensation expense			13,072						10,108
Non-cash lease adjustment			(159)						(127)
Provision for credit losses			195						300
Inventory write-down			274						330
Loss on foreign currency transactions			297						—
Changes in operating assets and liabilities:
Accounts receivable, net			(13,317)						3,929
Inventory			(7,027)						(6,282)
Prepaid expenses and other current assets			1,167						576
Other assets			(431)						(395)
Accounts payable			1,536						3,754
Accrued compensation			(4,688)						(6,561)
Accrued interest expense			49						25
Deferred revenue			628						235
Other liabilities			180						390
Net cash used in operating activities			(38,127)						(16,980)
Cash flows from investing activities:
Purchases of property and equipment			(2,914)						(1,836)
Net cash used in investing activities			(2,914)						(1,836)
Cash flows from financing activities:
Proceeds from issuance of common stock from the exercise of stock options			222						1,298
Net cash provided by financing activities			222						1,298
Effect of exchange rates on cash, cash equivalents and restricted cash			(42)						—
Net decrease in cash, cash equivalents and restricted cash			(40,861)						(17,518)
Cash, cash equivalents and restricted cash
Beginning of the period			289,540						336,763
End of the period			$	248,679					$	319,245
Reconciliation of cash, cash equivalents and restricted cash to balance sheets:
Cash and cash equivalents			$	245,641					$	316,207
Restricted cash			3,038						3,038
Cash, cash equivalents and restricted cash in balance sheets			$	248,679					$	319,245
Supplemental cash flow information
Interest paid			$	801					$	885
Non-cash investing and financing activities
Property and equipment included in accounts payable and accrued expenses			$	1,061					$	1,388

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

PROCEPT BioRobotics Corporation

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.    Organization

Description of Business

PROCEPT BioRobotics Corporation, or the Company, was incorporated in the state of California in 2007 and its headquarters are located in San Jose, California. In April 2021, the Company re-incorporated in the state of Delaware. The Company received U.S. Food and Drug Administration clearance in December 2017 to market its AquaBeam® Robotic System, an automated surgical robot providing tissue removal for the treatment of benign prostatic hyperplasia, a prostate gland enlargement condition. On August 20, 2024, the Company received 510(k) clearance from the FDA for its next generation robot system, HYDROS® Robotic System.

2.    Summary of Significant Accounting Policies

Basis of Preparation

The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and pursuant to the rules and regulations of the United States Securities and Exchange Commission or SEC. These condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Unaudited Interim Financial Statements

The accompanying balance sheet as of March 31, 2026, the statements of operations and comprehensive loss and cash flows for the three months ended March 31, 2026 and 2025, and the statements of stockholders’ equity as of March 31, 2026 and 2025, are unaudited. The financial data and other information disclosed in these notes to the financial statements related to March 31, 2026, and the three months ended March 31, 2026 and 2025, are also unaudited. The accompanying balance sheet as of December 31, 2025 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission.

The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to a fair statement of the Company’s financial position as of March 31, 2026, and the results of its operations and cash flows for the three months ended March 31, 2026 and 2025. The results for the three months ended March 31, 2026, are not necessarily indicative of results to be expected for the year ending December 31, 2026, or for any other interim period or for any future year and should be read in conjunction with the annual consolidated financial statements included in the Company’s Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed consolidated financial statements. Management uses significant judgment when making estimates related to its allowance for credit losses, excess and obsolete inventory reserves, stock-based compensation expense, right-of-use lease asset, lease liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.

8

Recently Adopted Accounting Pronouncements

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. ASU 2025-05 provides a practical expedient and, if applicable, an accounting policy election to simplify the measurement of credit losses for certain receivables and contract assets. The amendments are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted in any interim or annual period in which financial statements have not yet been issued or made available for issuance. The Company adopted this ASU effective January 1, 2026. The ASU did not have a material impact to the Company’s financial statements.

Recent Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASUs require public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the impact this ASU will have on its financial statement disclosures.

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU removes all references to prescriptive and sequential software development stages (referred to as “project stages”) and requires companies to start capitalizing software costs when both of the following occur: (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the “probable-to complete recognition threshold”). ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The adoption of this ASU is not expected to have a material impact to the Company’s financial statements.

3.    Fair Value Measurements

The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):

			March 31, 2026																								December 31, 2025
			Level 1						Level 2						Level 3						Total						Level 1						Level 2						Level 3						Total
Cash and cash equivalents:
Cash			$	12,229					$	—					$	—					$	12,229					$	11,417					$	—					$	—					$	11,417
Cash equivalents			233,412						—						—						233,412						275,086						—						—						275,086
Total cash and cash equivalents			$	245,641					$	—					$	—					$	245,641					$	286,503					$	—					$	—					$	286,503

Cash equivalents consist primarily of money market deposit funds.

The carrying value of the Company’s long-term debt approximates fair value as the debt bears interest at variable SOFR rates at March 31, 2026 and December 31, 2025, which is observable at commonly quoted intervals for the full term of the loan, and therefore, is considered a Level 2 item in the fair value hierarchy.

9

4.    Balance Sheet Components

Allowance for credit losses (in thousands):

						March 31,						December 31,
						2026						2025
Beginning balance						$	1,059					$	840
Net changes during the period						195						219
Ending balance						$	1,254					$	1,059

Inventory (in thousands):

			March 31,						December 31,
			2026						2025
Raw materials			$	23,334					$	18,617
Work-in-process			12,832						13,447
Finished goods			41,370						38,630
Total inventory			$	77,536					$	70,694

Property and equipment, net, (in thousands):

			March 31,						December 31,
			2026						2025
Manufacturing and computer equipment, and furniture and fixtures			$	26,275					$	21,842
Laboratory equipment			4,675						3,590
Rental equipment			499						385
Leasehold improvements			13,225						13,225
Construction in progress			1,483						4,109
Total property and equipment			46,157						43,151
Less: accumulated depreciation and amortization			(14,418)						(12,752)
Total property and equipment, net			$	31,739					$	30,399

Deferred commission costs, (in thousands):

									March 31,						December 31,
									2026						2025
Reported as:
Prepaid expenses and other current assets									$	469					$	438
Other assets									$	1,273					$	1,273

5.    Long-Term Debt

Term Loan Facility

In October 2022, the Company entered into a loan and security agreement (as amended, “the Agreement”) with Canadian Imperial Bank of Commerce, or CIBC. The Agreement provides for a senior secured term loan facility in the aggregate principal amount of $52.0 million (the "Term Loan Facility") which was borrowed in full.

The Term Loan Facility is scheduled to mature on the fifth anniversary of the closing date (the “Maturity Date”). The Company has the option to prepay the Term Loan Facility without any prepayment charge or fee.

10

The loan borrowed under the Term Loan Facility bears interest at an annual rate equal to the secured overnight financing rate or SOFR (calculated based on an adjustment of .10%, .15% and .25%, respectively, for one-month, three-month or six-month term SOFR as of a specified date, subject to a floor of 1.5%) plus an applicable margin of 2.25%. The weighted-average interest rate for the periods ending March 31, 2026 and 2025 were 5.9%, and 6.6%, respectively.

The obligations under the Agreement are secured by substantially all of the Company's assets, including its intellectual property and by a pledge all of the Company's equity interests in its U.S. subsidiaries and 65% of the Company's equity interests in its non-U.S. subsidiaries that are directly owned by the Company.

In August 2025, the Company entered into a second amendment to the Agreement (the “Second Amendment”), which, among other things, modified the repayment terms such that the entire principal amount outstanding is now due on the Maturity Date, replacing the prior repayment schedule of interest-only payments followed by monthly principal amortization payments. Additionally, the Second Amendment modified the Company’s minimum cash holdings requirement at CIBC as follows: (a) if the Company’s cash and cash equivalents is less than $50.0 million, then the Company is required to maintain 100% of its cash and cash equivalents at CIBC; or (b) if the Company’s cash and cash equivalents is greater than or equal to $50.0 million, then the Company is required to maintain the greater of $50.0 million or 50% of its cash and cash equivalents at CIBC, with amounts exceeding $50.0 million permitted to be held outside of CIBC in collateral accounts managed by CIBC.

Under the Loan Agreement, if the Company maintains less than $100.0 million in available cash, then the Company is required to meet either one of two financial covenants: a minimum unrestricted cash covenant or a minimum revenue and growth covenant. If the Company maintains at least $100.0 million in available cash, then it is not required to meet such financial covenants. As of March 31, 2026, the Company was in compliance with all debt covenants.

Future minimum annual debt repayments are as follows (in thousands):

Fiscal Year			Amount
2026			—
2027			52,000
Total minimum payments			52,000
Less: amount representing unamortized debt discount			(336)
Present value of future payments			$	51,664

11

6.    Leases

Facility Lease

In December 2021, the Company entered into a lease for two existing buildings, comprising approximately 158,221 square feet of space, located in San Jose, California. The lease commenced in July 2022, and will continue for 122 months following thereafter, with two five year options to extend the term of the lease.

Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $1.4 million and $1.6 million for the three months ended March 31, 2026 and 2025.

Future minimum annual operating lease payments are as follows (in thousands):

As of March 31, 2026			Amount
2026			$	3,319
2027			4,808
2028			4,952
2029			5,101
2030			5,254
Thereafter			11,943
Total minimum payments			35,377
Less: amount representing interest/unamortized debt discount			(9,045)
Present value of future payments			26,332
Less: current portion			(2,358)
Non-current portion			$	23,974

As of March 31, 2026 and December 31, 2025, the Company’s security deposit is in the form of, and recorded as, restricted cash.

Lessor Information for Robotic Systems

Contractual maturities of gross lease receivables as of March 31, 2026 are as follows (in thousands):

Fiscal Year						Amount
2026						$	1,048
2027						1,274
2028						1,274
2029						1,137
2030 and thereafter						747
Total						$	5,480

									March 31,						December 31,
									2026						2025
Gross receivables									$	5,480					$	5,829
Unearned interest income									(701)						(1,028)
Net investment in sales-type leases									$	4,779					$	4,801

The components of income from sales-type leases are as follows:

12

			Three Months Ended March 31,
			2026									2025
Sales-type lease revenue			$	—								$	—
Interest income			$	84								$	38

Leases receivable relating to sales-type lease arrangements are presented on the Company’s consolidated balance sheets as follows (in thousands):

									March 31,						December 31,
									2026						2025
Reported as:
Accounts receivable									$	1,013					$	905
Other assets									3,766						3,896
Net investment in sales-type leases									$	4,779					$	4,801

13

7.    Stock-Based Compensation

Total stock-based compensation recognized, before taxes, are as follows (in thousands):

			Three Months Ended March 31,
			2026						2025
Cost of sales			$	2,694					$	2,187
Research and development			3,241						2,525
Sales, general and administrative			8,583						6,569
Stock-based compensation capitalized in inventory			(1,446)						(1,173)
Total stock-based compensation			$	13,072					$	10,108

Stock Options

The Company had 8.0 million shares available for grant as of March 31, 2026 under the 2021 Equity Incentive Award Plan, or 2021 Plan.

A summary of the Company’s stock option activity and related information are as follows (options in thousands):

			Three Months Ended
			March 31, 2026
			Number of Shares						Weighted-Average Exercise Price
Outstanding, beginning of period			3,444						$	17.00
Granted			293						25.35
Exercised			(56)						3.96
Forfeited			—						—
Outstanding, end of period			3,681						17.87
Vested and expected to vest			3,681						17.87
Exercisable			2,774						11.75

As of March 31, 2026 and December 31, 2025, the aggregate pre-tax intrinsic value of options outstanding and exercisable was $44.7 million and $61.0 million, respectively, and the aggregate pre-tax intrinsic value of options outstanding were $44.7 million and $61.0 million, respectively. The aggregate pre-tax intrinsic value of options exercised was $1.4 million and $8.7 million during the three months ended March 31, 2026 and 2025, respectively.

As of March 31, 2026, there was a total of $16.9 million of unrecognized stock-based compensation expense related to stock options.

The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table:

			Three Months Ended March 31,
			2026						2025
Expected life (years)			6.0						6.0
Expected volatility			64		%				58		%
Risk-free interest rate			3.8		%				4.0		%
Expected dividend rate			—		%				—		%
Weighted-average fair value			$	15.60					$	35.00

Restricted Stock Units

14

A summary of the Company’s restricted stock unit, or RSU, activity and related information are as follows (RSUs in thousands):

			Three Months Ended
			March 31, 2026
			Number of Shares						Weighted-Average Fair Value
Unvested, beginning of period			2,346						$	48.63
Awarded			2,195						25.54
Forfeited			(71)						43.29
Vested			(484)						47.28
Unvested, end of period			3,986						36.18

As of March 31, 2026, there was a total of $130.3 million of unrecognized stock-based compensation expense related to RSUs.

Performance Stock Units

The 2021 Plan provides for issuance of performance stock units, or PSUs. PSUs granted are contingent upon the achievement of predetermined market, performance, and service conditions. PSUs are awarded to executives of the Company and generally time vest over a period of up to three years. Vesting is also generally contingent upon achievement of applicable performance metrics. PSU expense is recognized over the requisite service period.

During the three months ended March 31, 2026, the Company awarded PSU shares with both a performance and service condition.

A summary of the Company’s PSU activity and related information are as follows (PSUs in thousands):

			Three Months Ended
			March 31, 2026
			Number of Shares						Weighted-Average Fair Value
Unvested, beginning of period			115						$	67.62
Awarded			285						25.35
Forfeited			—						—
Vested			(34)						82.14
Performance change			(52)						66.36
Unvested, end of period			314						27.85

As of March 31, 2026, total unrecognized stock-based compensation related to unvested PSUs was $7.6 million.

Employee Stock Purchase Plan

During the period ended March 31, 2026, there were no stock purchases under the Employee Stock Purchase Plan, or ESPP. As of March 31, 2026, there was approximately $2.1 million of unrecognized cost related to the Employee Stock Purchase Plan, or ESPP. This cost is expected to be recognized over a weighted average period of 0.4 years. As of March 31, 2026, a total of 2.4 million shares were available for issuance under the ESPP.

15

8.    Net Loss Per Share

Net loss per share was determined as follows (in thousands, except per share amounts):

			Three Months Ended March 31,
			2026						2025
Net loss			$	(31,638)					$	(24,737)
Weighted-average common stock outstanding			56,511						54,917
Net loss per share, basic and diluted			$	(0.56)					$	(0.45)

The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands):

			March 31,
			2026						2025
Stock options			3,681						3,744
Restricted and performance stock units			4,300						2,235
Employee stock purchase plan			336						56
Total			8,317						6,035

9.    Revenue

The following table presents revenue disaggregated by type and geography (in thousands):

			Three Months Ended March 31,
			2026						2025
U.S.
System sales and rentals			$	23,386					$	18,687
Handpieces and other consumables			43,018						38,011
Service			5,614						3,596
Total U.S. revenue			72,018						60,294
Outside of U.S.
System sales and rentals			3,853						3,853
Handpieces and other consumables			6,372						4,477
Service			889						538
Total outside of U.S. revenue			11,114						8,868
Total revenue			$	83,132					$	69,162

During the three months ended March 31, 2026, the Company recognized $5.2 million of revenue, that was included in the deferred revenue balance as of December 31, 2025. During the three months ended March 31, 2025, the Company recognized $4.0 million of revenue, that was included in the deferred revenue balance as of December 31, 2024.

16

10.    Segment, Geographical, and Customer Concentration

The Company operates as a single operating segment. The Company’s chief operating decision maker, or CODM, its Chief Executive Officer, reviews the Company’s forecast, as well as budget to actual financial information, as key inputs to making decisions on resource allocation and assessing the performance of the business. The CODM monitors budget versus actual results using income (loss) from operations, income (loss) before provision for income taxes, and net income (loss).

Significant expenses within income from operations, as well as within net income (loss), include cost of goods sold, research and development expenses, and selling, general and administrative expenses, which are each separately presented on the Company’s consolidated statements of operations. Other segment items within net income (loss) include interest expense, and interest and other income, net on an aggregate basis for the purposes of allocating resources and evaluating financial performance.

The Company’s assets are primarily based in the United States.

No customers accounted for more than 10% of revenue during the three months ended March 31, 2026 and 2025.

No customer accounted for more than 10% of accounts receivable at March 31, 2026 and December 31, 2025.

The following table presents revenue by significant geographical locations for the periods indicated:

						Three Months Ended March 31,
						2026						2025
United States						87		%				87		%
Outside the United States						13		%				13		%

No individual country outside the United States accounted for more than 10% of the Company’s revenue for the periods presented.

11.    Commitments and Contingencies

Guarantees and Indemnifications

In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any material claims or been required to defend any action related to its indemnification obligations. As of March 31, 2026 and December 31, 2025, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

Legal Contingencies

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of our business. The Company is not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on the business. Regardless of outcome, litigation can have an adverse impact on the Company due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.

A liability and related charge to earnings are recorded in the financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information.

12.    Defined Contribution Plan

The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on both a pre-tax and after-tax basis. Employer contributions were $1.2 million and $0.9 million for the three months ended March 31, 2026 and 2025.

17

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this report. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in the section titled “Risk Factors” and elsewhere in this report. Please also see the section titled “Cautionary Note Regarding Forward-Looking Statements.”

Overview

We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes. We believe that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions. We designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that is independent of prostate size and shape, and delivers resection independent of surgeon experience. We have developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. As of March 31, 2026, we had an install base of 971 AquaBeam Robotic Systems and HYDROS Robotic Systems globally, including 765 in the United States.

Our U.S. pivotal trial, the WATER study, is the only FDA pivotal study randomized against transurethral resection of prostate, or TURP, which is the historical standard of care for the surgical treatment of BPH. In this study, Aquablation therapy demonstrated superior safety and non-inferior efficacy compared to TURP across prostate sizes between 30 ml and 80 ml, and superior efficacy in a subset of patients with prostates larger than 50 ml. We have established strong relationships with key opinion leaders, or KOLs, within the urology community and collaborated with key urological societies in global markets. This support has been instrumental in facilitating broader acceptance and adoption of Aquablation therapy. As a result of our strong KOL network and our compelling clinical evidence, Aquablation therapy has been added to clinical guidelines of various professional associations, including the American Urological Association.

We manufacture the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at our facility in San Jose, California. This includes supporting the supply chain distribution and logistics of the various components. Components, sub-assemblies and services required to manufacture our products are purchased from numerous global suppliers. Each robotic system is shipped to our customers with a third-party manufactured ultrasound system and probe. We utilize a well-known third-party logistics provider located in the United States and the Netherlands to ship our products to our customers globally.

We generated revenue of $83.1 million and incurred a net loss of $31.6 million for the three months ended March 31, 2026, compared to revenue of $69.2 million and a net loss of $24.7 million for the three months ended March 31, 2025. As of March 31, 2026, we had cash and cash equivalents of $245.6 million and an accumulated deficit of $673.2 million.

18

Factors Affecting Our Performance

We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations for the foreseeable future. While these factors may present significant opportunities for us, they also pose significant risks and challenges that we must address. See the section titled “Risk Factors” for more information. These factors include:

•Grow our install base of robotic systems: As of March 31, 2026, we had an install base of 971 robotic systems globally, including 765 in the United States. In the United States, we are initially focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery. We target approximately 2,700 hospitals that perform resective BPH procedures in the United States. To penetrate these hospitals, we expect to continue to increase our direct team of capital sales representatives, who are focused on driving system placement within hospitals by engaging with key surgeons and decision makers to educate them about the compelling value proposition of Aquablation therapy. As we increase our install base of robotic systems, we expect our revenue to increase as a result of the system sale and resulting utilization.

•Increase system utilization: Our revenue is significantly impacted by the utilization of our robotic systems. Once we place a system within a hospital our objective is to establish Aquablation therapy as the surgical treatment of choice for BPH. Within each hospital we are initially focused on targeting urologists who perform medium-to-high volumes of resective procedures and converting their resective cases to Aquablation therapy. To accomplish this, we will continue expanding our team of highly trained Aquablation representatives and clinical specialists who are focused on driving system utilization within the hospital, providing education and training support and ensuring excellent user experiences. As urologists gain experience with Aquablation therapy, we expect to leverage their experiences to capture more surgical volumes and establish Aquablation therapy as the surgical standard of care.

•Reimbursement and coverage decisions by third-party payors. Healthcare providers in the United States generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to cover all or part of the cost of procedures using our robotic system. The revenue we are able to generate from sales of our products depends in large part on the availability of sufficient reimbursement from such payors. Effective in 2021, all local MACs, representing 100% of eligible Medicare patients, issued final positive local coverage determinations to provide Medicare beneficiaries with access to Aquablation therapy in all 50 states. We believe that these favorable coverage decisions have been a catalyst for hospital adoption of our robotic systems. We believe our strong body of clinical evidence and support from key societies, supplemented by the momentum from Medicare coverage, have led to favorable coverage decisions from many large commercial payors. We plan to leverage these successes in our active discussions with commercial payors to establish additional positive national and regional coverage policies. We believe that additional commercial payor coverage will contribute to increasing utilization of our system over time. Outside of the United States, we have ongoing efforts in key markets to expand established coverage and further improve patient access to Aquablation therapy.

•Cost of sales. The results of our operations will depend, in part, on our ability to increase our gross margins by more effectively managing our costs to produce our robotic systems and single-use disposable handpieces, and to scale our manufacturing operations efficiently. We anticipate that as we expand our sales and marketing efforts and drive further sales growth, our purchasing costs on a per unit basis may decrease, and in turn improve our gross margin. As our commercial operations continue to grow, we expect to continue to realize operating leverage through increased scale efficiencies.

•Investment in research and development to drive continuous improvements and innovation. We are currently developing additional and next generation technologies to support and improve Aquablation therapy to further satisfy the evolving needs of surgeons and their patients as well as to further enhance the usability and scalability of our robotic systems. We also plan to leverage our treatment data and software development capabilities to integrate artificial intelligence and machine learning to enable computer-

19

assisted anatomy recognition and improved treatment planning and personalization. Our future growth is dependent on these continuous improvements which require significant resources and investment.

Components of Our Results of Operations

Revenue

We generate our revenue primarily from the sales and rentals of our robotic systems, sales of our single-use disposable handpieces that are used during each surgery performed with our system, and related accessories. Additionally, we also derive revenue from service and repair and extended service contracts with our existing customers. We expect our revenue to increase in absolute dollars for the foreseeable future as we continue to focus on driving adoption of Aquablation therapy, and increased system utilization, though it may fluctuate from quarter to quarter.

The following table presents revenue by significant geographical locations for the periods indicated:

			Three Months Ended March 31,
			2026						2025
United States			87		%				87		%
Outside the United States			13		%				13		%

We expect that both our United States and international revenue will increase in the near term as we continue to expand the install base of our robotic systems and increase the related single-use disposable handpieces sold. We expect our increase in revenue in absolute dollars to be larger in the United States.

Cost of Sales and Gross Margin

Cost of sales consists primarily of manufacturing overhead costs, material costs, warranty and service costs, direct labor, scrap and other direct costs such as shipping costs. A significant portion of our cost of sales currently consists of manufacturing overhead costs. These overhead costs include compensation for personnel, including stock-based compensation, facilities, equipment and operations supervision, quality assurance and material procurement. We expect our cost of sales to increase in absolute dollars for the foreseeable future primarily as, and to the extent, our revenue grows, or we make additional investments in our manufacturing capabilities, though it may fluctuate from period to period.

We calculate gross margin percentage as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily, product and geographic mix and the resulting average selling prices, production volumes, manufacturing costs and product yields, and to a lesser extent the implementation of cost reduction strategies. We expect our gross margin to increase over the long term as our production volume increases and as we spread the fixed portion of our manufacturing overhead costs over a larger number of units produced, thereby significantly reducing our per unit manufacturing costs, though it may fluctuate from quarter to quarter. Our gross margins can fluctuate due to geographic mix. To the extent we sell more systems and handpieces in the United States, we expect our margins will increase due to the higher average selling prices as compared to sales outside of the United States.

Operating Expenses

Research and Development

Research and development, or R&D, expenses consist primarily of engineering, product development, regulatory affairs, consulting services, clinical trial expenses, materials, depreciation and other costs associated with products and technologies being developed. These expenses include employee and non-employee compensation, including stock-based compensation, supplies, materials, quality assurance expenses, consulting, related travel expenses and facilities expenses. We expect our R&D expenses to increase in absolute dollars for the foreseeable future as we make strategic investments in R&D, continue to develop and enhance existing products and

20

technologies, though it may fluctuate from quarter to quarter. However, over time, we expect our R&D expenses to decrease as a percentage of revenue.

Selling, General and Administrative

Selling, general and administrative, or SG&A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling, marketing, clinical affairs, professional education, finance, information technology, and human resource functions. SG&A expenses also include commissions, training, travel expenses, promotional activities, conferences, trade shows, professional services fees, audit fees, legal fees, insurance costs, bad debt expense and general corporate expenses including allocated facilities-related expenses. Post-market clinical study expenses include trial design, site reimbursement, data management and travel expenses. We expect our SG&A expenses to increase in absolute dollars for the foreseeable future as we expand our commercial infrastructure in order for us to execute on our long-term growth plan, though it may fluctuate from quarter to quarter. However, over time, we expect our SG&A expenses to decrease as a percentage of revenue.

Interest and Other Income, Net

Interest Expense

Interest expense consists primarily of interest expense from our long-term debt.

Interest and Other Income, Net

Interest and other income, net, consists primarily of interest income from our cash and cash equivalents balances.

Provision for Income Taxes

The provision for income taxes consists primarily of foreign income taxes, as the Company does not have U.S. federal or state taxable income for the periods presented. As we expand the scale of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for income taxes in the future. We have a valuation allowance for our United States deferred tax assets, including federal and state non-operating loss carryforwards. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized by way of expected future taxable income in the United States.

21

Results of Operations

The following tables show our results of operations for the periods indicated:

			Three Months Ended March 31,												Change
			2026						2025						$						%
			(in thousands, except percentages)
Revenue			$	83,132					$	69,162					$	13,970					20		%
Cost of sales			29,185						25,001						4,184						17
Gross profit			53,947						44,161						9,786						22
Gross margin			65		%				64		%
Operating expenses:
Research and development			21,465						16,402						5,063						31
Selling, general and administrative			65,088						55,197						9,891						18
Total operating expenses			86,553						71,599						14,954						21
Loss from operations			(32,606)						(27,438)						5,168						19
Interest expense			(818)						(877)						(59)						(7)
Interest and other income, net			1,743						3,531						(1,788)						(51)
Loss before provision for income taxes			(31,681)						(24,784)						(6,897)						28
Provision for income taxes			(43)						(47)						4						(9)
Net loss			$	(31,638)					$	(24,737)					$	6,901					28

Comparison of Three Months Ended March 31, 2026 and 2025

Revenue

			Three Months Ended March 31,												Change
			2026						2025						$						%
			(in thousands, except percentages)
System sales and leases			$	27,239					$	22,540					$	4,699					21		%
Handpieces and other consumables			49,390						42,488						6,902						16
Service			6,503						4,134						2,369						57
Total revenue			$	83,132					$	69,162					$	13,970					20

Revenue increased $14.0 million, or 20%, to $83.1 million during the three months ended March 31, 2026, compared to $69.2 million during the three months ended March 31, 2025. The growth in revenue was primarily attributable to $72.0 million in revenue derived from the United States for the three months ended March 31, 2026. The increase was due to higher sales volumes of system sales, handpieces, other consumables, and service contracts.

Cost of Sales and Gross Margin

Cost of sales increased $4.2 million, or 17%, to $29.2 million during the three months ended March 31, 2026, compared to $25.0 million during the three months ended March 31, 2025. The increase in cost of sales was primarily attributable to the growth in the number of units sold.

Gross margin increased to 65% during the three months ended March 31, 2026, compared to 64% for the three months ended March 31, 2025. The increase in gross margin was primarily attributable to the growth in unit sales, which allowed us to spread the fixed portion of our manufacturing overhead costs over more production units, and to a lesser extent, an increase in average selling prices on both our system sales and handpieces.

22

Research and Development Expenses

R&D expenses increased $5.1 million, or 31%, to $21.5 million during the three months ended March 31, 2026, compared to $16.4 million during the three months ended March 31, 2025. The increase in R&D expenses was primarily due to employee-related expenses of our R&D organization such as salaries and wages and stock-based compensation. These expenses support ongoing product improvements and the development of additional and next generation technologies.

Selling, General and Administrative Expenses

SG&A expenses increased $9.9 million, or 18%, to $65.1 million during the three months ended March 31, 2026, compared to $55.2 million during the three months ended March 31, 2025. The increase in SG&A expenses was primarily due to employee-related expenses of our sales and marketing organization such as salaries and wages and stock-based compensation expense primarily to expand the commercial organization, and employee-related expenses of our administrative organization such as salaries and wages and stock-based compensation expense, to drive and support our growth in revenue.

Interest Expense

Interest expense decreased approximately $0.1 million, or 7%, to $0.8 million during the three months ended March 31, 2026, compared to $0.9 million during the three months ended March 31, 2025. The decrease in interest expense was primarily due to a decrease in the interest rate as compared to the prior period.

Interest and Other Income, Net

Interest and other income, net, decreased $1.8 million for the three months ended March 31, 2026. The decrease was primarily due to a decrease in interest income, which was due to our decreased cash balances.

Provision for Income Taxes

Provision for income taxes was immaterial for all periods presented.

Liquidity and Capital Resources

Overview

As of March 31, 2026, we had cash and cash equivalents of $245.6 million, an accumulated deficit of $673.2 million, and $52.0 million outstanding on our loan facility. We expect our expenses will increase for the foreseeable future, as we continue to make substantial investments in sales and marketing, operations and research and development. Our future funding requirements will depend on many factors, including:

•the degree and rate of market acceptance of our products and Aquablation therapy;

•the scope and timing of investment in our sales force and expansion of our commercial organization;

•the scope, rate of progress and cost of our current or future clinical trials and registries;

•the cost of our research and development activities;

•the cost and timing of additional regulatory clearances or approvals;

•the costs associated with any product recall that may occur;

•the costs associated with a regulatory or government action or other litigation;

•the costs associated with the manufacturing of our products at increased production levels;

•the costs of attaining, defending and enforcing our intellectual property rights;

23

•whether we acquire third-party companies, products or technologies;

•the terms and timing of any other collaborative, licensing and other arrangements that we may establish;

•the emergence of competing technologies or other adverse market developments; and

•the rate at which we expand internationally.

Based on our operating plan, we currently believe that our existing cash and cash equivalents and anticipated revenue will be sufficient to meet our capital requirements and fund our operations through at least the next twelve months from the issuance date of the financial statements. We have based this estimate on assumptions that may prove to be wrong, and we may need to utilize additional available capital resources. If these sources are insufficient to satisfy our liquidity requirements, we may seek to sell additional public equity or debt securities or obtain an additional credit facility. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Additional financing may not be available at all, or in amounts or on terms unacceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products.

Indebtedness

In October 2022, we entered into a loan and security agreement with Canadian Imperial Bank of Commerce. The agreement provides for a senior secured term loan facility in the aggregate principal amount of $52.0 million (the “Term Loan Facility”), which was borrowed in full.

The Term Loan Facility is scheduled to mature on October 6, 2027, the fifth anniversary of the closing date, or the Maturity Date. We have the option to prepay the Term Loan Facility without any prepayment charge or fee.

The loan borrowed under the Term Loan Facility bears interest at an annual rate equal to the secured overnight financing rate ("SOFR") (calculated based on an adjustment of 0.10%, 0.15% and 0.25%, respectively, for one-month, three-month or six-month term SOFR as of a specified date, subject to a floor of 1.5%) plus an applicable margin of 2.25%.

The obligations under the loan and security agreement are secured by substantially all of our assets, including its intellectual property and by a pledge of all of our equity interests in its U.S. subsidiaries and 65% of our equity interests in its non-U.S. subsidiaries that are directly owned by us.

In August 2025, we entered into a second amendment to the loan and security agreement (the “Second Amendment”), which, among other things, modified the repayment terms such that the entire principal amount outstanding is now due on the Maturity Date, replacing the prior repayment schedule of interest-only payments followed by monthly principal amortization payments. After giving effect to the Second Amendment, we are obligated to maintain in collateral accounts held at the lender (a) if our cash and cash equivalents is less than $50.0 million, 100% of our cash and cash equivalents; or (b) if our cash and cash equivalents is greater than or equal to $50.0 million, the greater of (i) $50.0 million or (ii) 50% of our cash and cash equivalents, with amounts exceeding $50.0 million permitted to be held outside of the lender in collateral accounts managed by the lender.

The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants, and events of default. Under the loan and security agreement, if we maintain less than $100.0 million in available cash, then we are required to meet either one of two financial covenants: a minimum unrestricted cash covenant or a minimum revenue and growth covenant. The minimum unrestricted cash covenant requires that we maintain cash reserve not less than the greater of (i) $20.0 million, (ii) the absolute value of EBITDA losses (if any) for the most recent consecutive four-month period then ended or (iii) the aggregate outstanding principal amount of $52.0 million. The minimum revenue and growth covenant requires our revenue, for the consecutive twelve-month period as of each measurement date, of not less than $50.0 million and of at least 115% as of the last

24

day of the consecutive twelve-month period of the immediately preceding year. If we maintain at least $100.0 million in available cash, then we are not required to meet such financial covenants.

Cash Flows

The following table summarizes our cash flows for the periods presented:

			Three Months Ended March 31,
			2026						2025
			(in thousands)
Net cash (used in) provided by:
Operating activities			$	(38,127)					$	(16,980)
Investing activities			(2,914)						(1,836)
Financing activities			222						1,298
Effect of exchange rates on cash, cash equivalents and restricted cash			(42)						—
Net decrease in cash, cash equivalents and restricted cash			$	(40,861)					$	(17,518)

Net Cash Used in Operating Activities

During the three months ended March 31, 2026, net cash used in operating activities was $38.1 million, consisting primarily of a net loss of $31.6 million and an increase in net operating assets of $21.9 million, partially offset by non-cash charges of $15.4 million. The cash used in operations was primarily due to our net loss due to the increase in operating expenses to support our commercialization and development activities. The expansion of our commercialization activities resulted in an increase in accounts receivable, inventory, and accounts payable. Non-cash charges consisted primarily of stock-based compensation, depreciation, and reserves for excess and obsolete inventory.

During the three months ended March 31, 2025, net cash used in operating activities was $17.0 million, consisting primarily of a net loss of $24.7 million and an increase in net operating assets of $4.3 million, partially offset by non-cash charges of $12.1 million. The cash used in operations was primarily due to our net loss due to the increase in operating expenses to support our commercialization and development activities. The expansion of our commercialization activities resulted in an increase in inventory and accounts payable, partially offset by a decrease in accounts receivable, due to timing of cash receipts. Non-cash charges consisted primarily of stock-based compensation, depreciation, and reserves for excess and obsolete inventory.

Net Cash Used in Investing Activities

During the three months ended March 31, 2026, net cash used in investing activities was $2.9 million, consisting of purchases of property and equipment. During the three months ended March 31, 2025, net cash used in investing activities was $1.8 million, consisting of purchases of property and equipment.

Net Cash Provided by Financing Activities

During the three months ended March 31, 2026, net cash provided by financing activities was $0.2 million, consisting of proceeds from exercises of stock options. During the three months ended March 31, 2025, net cash provided by financing activities was $1.3 million, consisting of proceeds from exercises of stock options.

Contractual Commitments and Contingencies

The information included in Note 11 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have any off-balance sheet arrangements, such as structured finance, special purpose entities or variable interest entities.

25

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in our audited consolidated financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in our Annual Report on Form 10-K dated February 26, 2026, or Annual Report, and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report. There have been no material changes to our significant accounting policies during the three months ended March 31, 2026.

Recent Accounting Pronouncements

The information included in Note 2 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our market risks related to interest rate, credit, foreign currency exchange rates, and effects of inflation are described in Part II Item 7A, “Quantitative and Qualitative Disclosures About Market Risk”, of our 2025 Annual Report on Form 10-K. Our exposure to market risks has not changed materially since December 31, 2025.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of March 31, 2026, our disclosure controls and procedures were effective at the reasonable assurance level.

Limitations on Effectiveness of Disclosure Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.

Item 1A. Risk Factors

Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026. The risks and uncertainties disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. During the three months ended March 31, 2026, there were no material changes to our previously disclosed risk factors. Besides risk factors disclosed in the Annual Report and this Quarterly Report, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.

These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the quarter ended March 31, 2026, no director or officer of the Company informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K), except as follows:

On March 18, 2026, Kevin Waters, the Company’s Chief Financial Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Waters Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Waters Rule 10b5-1 Plan was entered into in accordance with the Company’s policies regarding transactions and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Waters Rule 10b5-1 Plan provides for the potential sale of up to 59,127 shares of the Company’s common stock during various specified trading periods through June 17, 2027.

27

Item 6. Exhibits

The following exhibits are filed or furnished as a part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit No.						Exhibit Description
3.1						Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on September 21, 2021)
3.2						Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K filed on September 21, 2021)
10.1*						Amended and Restated 2021 Employee Stock Purchase Plan
31.1*						Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*						Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**						Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**						Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS						Inline XBRL Instance Document – the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document.
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*						Cover Page Interactive Data File (embedded within the Inline XBRL document)

__________________

*Filed herewith.

**    Furnished herewith.

28

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 30, 2026

PROCEPT BIOROBOTICS CORPORATION

(Registrant)

/s/ Larry Wood

Larry Wood

President and Chief Executive Officer

(principal executive officer)

/s/ Kevin Waters

Kevin Waters

EVP, Chief Financial Officer

(principal financial and accounting officer)

29

FAQ

How did PROCEPT BioRobotics (PRCT) perform financially in Q1 2026?

PROCEPT BioRobotics grew Q1 2026 revenue to $83.1 million, a 20% increase from $69.2 million in Q1 2025. Growth came from higher system sales, consumable handpieces, and service. However, the company reported a net loss of $31.6 million, larger than last year.

What was PROCEPT BioRobotics’ profitability and gross margin in Q1 2026?

The company remained unprofitable, posting a net loss of $31.6 million in Q1 2026 versus $24.7 million a year earlier. Gross margin improved slightly to 65%, up from 64%, as higher volumes helped spread fixed manufacturing costs and average selling prices increased modestly.

What is PROCEPT BioRobotics’ cash position and debt level after Q1 2026?

As of March 31, 2026, PROCEPT BioRobotics held $245.6 million in cash and cash equivalents and had $51.7 million of long-term debt outstanding under a $52.0 million term loan facility. Operating activities used $38.1 million of cash during the quarter, reflecting ongoing growth investments.

How large is PROCEPT BioRobotics’ installed base of robotic systems?

By March 31, 2026, the company had an installed base of 971 AquaBeam and HYDROS Robotic Systems worldwide, including 765 in the United States. This growing footprint supports recurring revenue from single-use handpieces, consumables, and service contracts tied to benign prostatic hyperplasia procedures.

How are U.S. and international sales trending for PROCEPT BioRobotics (PRCT)?

In Q1 2026, about 87% of revenue came from the United States and 13% from markets outside the U.S., matching the prior year’s mix. Both regions contributed to growth as more hospitals adopted Aquablation therapy and utilization of installed robotic systems increased.

What are PROCEPT BioRobotics’ main operating expense trends in Q1 2026?

Research and development expenses rose to $21.5 million, up 31%, supporting product improvements and new technologies. Selling, general and administrative expenses increased to $65.1 million, up 18%, as the company expanded its commercial, clinical, and administrative infrastructure to drive adoption of Aquablation therapy.